Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca: A Cancer J Clin. 2021;71(3):209–49.

Google Scholar 

Kendrick P, Kelly YO, Baumann MM, Compton K, Blacker BF, Daoud F, et al. The burden of stomach cancer mortality by county, race, and ethnicity in the USA, 2000–2019: a systematic analysis of health disparities. Lancet Reg Health Am. 2023;1:24.

Google Scholar 

Yang W, Hu R, Li GC, Zhou ML, Wang Y, Shen LJ, et al. Survival outcomes and patterns of failure after D2 dissection and adjuvant chemoradiotherapy for locally advanced gastric cancer: a retrospective study. Br J Radiol. 2018;91(1089):20170594.

Article  PubMed  PubMed Central  Google Scholar 

Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.

Article  CAS  PubMed  Google Scholar 

Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–57.

Article  PubMed  Google Scholar 

Noh S, Park S, Yang H, Chung H, Chung I, Kim S, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5‑year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389–96.

Article  CAS  PubMed  Google Scholar 

Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S‑1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.

Article  CAS  PubMed  Google Scholar 

Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.

Article  CAS  PubMed  Google Scholar 

Cats A, Jansen EP, van Grieken NC, Sikorska K, Lind P, Nordsmark M, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):616–28.

Article  CAS  PubMed  Google Scholar 

Jayanathan M, Erwin RP, Molacek N, Fluck M, Hunsinger M, Wild J, et al. MAGIC versus macDonald treatment regimens for gastric cancer: trends and predictors of multimodal therapy for gastric cancer using the national cancer database. Am J Surg. 2020;219(1):129–35.

Article  PubMed  Google Scholar 

Jabo B, Selleck MJ, Morgan JW, Lum SS, Bahjri KA, Aljehani M, et al. Comparison of perioperative chemotherapy with adjuvant chemoradiotherapy for resectable gastric cancer: findings from a population-based study. J Gastrointest Oncol. 2018;9(1):35.

Article  PubMed  PubMed Central  Google Scholar 

Malapati SJ, Singh SR, Kumar R, Abdalla A, Hadid TH. Perioperative chemotherapy versus adjuvant chemoradiation in resectable gastric cancer: a national cancer database analysis. 2020. pp. 7066–7066.

Google Scholar 

Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.

PubMed  Google Scholar 

Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3. 0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176–81.

Article  PubMed  Google Scholar 

Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide dutch D1D2 trial. Lancet Oncol. 2010;11:439–49.

Article  PubMed  Google Scholar 

van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388:2654–64.

Article  PubMed  Google Scholar 

Zaidi A, Khan A, Duval C, Haider K, Ahmed O, Dueck DA, et al. Comparison of perioperative chemotherapy versus postoperative chemoradiotherapy for operable stomach cancer: a western canadian province experience. Curr Oncol. 2021;28(2):1262–73.

Article  PubMed  PubMed Central  Google Scholar 

Fan M, Li G, Shen L, Zhang H, Liang L, Zhang Z. Identification of patients with lymph node metastasis from gastric cancer who may benefit from adjuvant chemoradiotherapy after D2 dissection—do N3 patients benefit from additional radiation? Br J Radiol. 2016;89(1059):20150758.

Article  PubMed  PubMed Central  Google Scholar 

Kim TH, Park SR, Ryu KW, Kim YW, Bae JM, Lee JH, et al. Phase 3 trial of postoperative chemotherapy alone versus Chemoradiation therapy in stage III–IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. Int J Radiat Oncol Biol Phys. 2012;84(5):e585–e92.

Article  CAS  PubMed  Google Scholar 

Janjigian YY, Van Cutsem E, Muro K, Wainberg Z, Al-Batran SE, Hyung WJ, Molena D, Marcovitz M, Ruscica D, Robbins SH, Negro A. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. Future Oncol. 2022;18(20):2465–73.

Article  CAS  PubMed  Google Scholar 

Lorenzen S, Götze TO, Thuss-Patience P, Biebl M, Homann N, Schenk M, Lindig U, Heuer V, Kretzschmar A, Goekkurt E, Haag GM. Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II/III DANTE/IKF–s633 trial. J Clin Oncol. 2024;42(4):410–20.

Article  CAS  PubMed  Google Scholar 

Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, Yasui H, Yabusaki H, Afanasyev S, Park YK, Al-Batran SE. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25(2):212–24.

Article  CAS  PubMed  Google Scholar 

Hofheinz RD, Hegewisch-Becker S, Kunzmann V, Thuss-Patience P, Fuchs M, Homann N, Graeven U, Schulte N, Merx K, Pohl M, Held S. Trastuzumab in combination with 5‑fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: a phase II trial of the arbeitsgemeinschaft internistische onkologie gastric cancer study group. Int J Cancer. 2021;149(6):1322–31.

Article  CAS  PubMed  Google Scholar